Lantern Pharma Inc (LTRN)
Healthcare
Biotechnology
2.60 $
-0.8%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Lantern Pharma Inc (LTRN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.1% of the shares are freely tradable; institutional investors hold 14.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
14.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
17.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
74.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
13Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BIOS CAPITAL MANAGEMENT, LP | 6.78 | 864,435 | -14.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.60 | 332,079 | +0.0 | 03/31/2026 |
| CM Management, LLC | 1.96 | 250,000 | +11.1 | 03/31/2026 |
| Renaissance Technologies Corp | 0.91 | 116,000 | +5.1 | 03/31/2026 |
| Geode Capital Management, LLC | 0.88 | 111,646 | +15.4 | 03/31/2026 |
| Westside Investment Management, Inc. | 0.39 | 50,050 | +39.4 | 03/31/2026 |
| Voss Capital LLC | 0.39 | 50,000 | +0.0 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.39 | 49,607 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 2.65 | 338,385 | +35.0 | 06/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.64 | 81,901 | +1.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.